Trastuzumab
- Generic Name
- Trastuzumab
- Brand Names
- Herceptin, Herceptin Hylecta, Herzuma, Kanjinti, Ontruzant, Perjeta-Herceptin, Phesgo, Trazimera, Herwenda, Ogivri, Zercepac, Tuznue
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 180288-69-1
- Unique Ingredient Identifier
- P188ANX8CK
- Background
Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth factor receptor (HER)-2+ metastatic bre...
- Indication
For the adjuvant treatment of HER2-overexpressing breast cancer, trastuzumab is indicated in several clinical settings: as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel; as part of a treatment regimen with docetaxel and carboplatin; or as monotherapy following multi-modality anthracycline-based th...
- Associated Conditions
- Breast Cancer, Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Adenocarcinoma of the Stomach, Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Stage I Breast Cancer
- Associated Therapies
- -
Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients
- Conditions
- Interventions
- First Posted Date
- 2007-01-30
- Last Posted Date
- 2018-08-09
- Lead Sponsor
- Bhuvaneswari Ramaswamy
- Target Recruit Count
- 26
- Registration Number
- NCT00428922
- Locations
- 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
🇺🇸University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Delayed Adjuvant Herceptin® Treatment in Patients With HER-2 Positive Breast Cancer
- Conditions
- First Posted Date
- 2007-01-29
- Last Posted Date
- 2016-08-01
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 75
- Registration Number
- NCT00427427
- Locations
- 🇺🇸
Revlon/UCLA Breast Center, Los Angeles, California, United States
Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-01-24
- Last Posted Date
- 2015-12-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 88
- Registration Number
- NCT00426556
- Locations
- 🇺🇸
Compassionate Cancer Care Medical Group Dept.ofCCCMG, Fountain Valley, California, United States
🇺🇸University of California at Los Angeles Dept.of UCLA Dept.ofMed., Los Angeles, California, United States
🇺🇸Cancer Centers of the Carolinas CC of C -Eastside, Greenville, South Carolina, United States
A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer
- First Posted Date
- 2006-12-15
- Last Posted Date
- 2016-09-21
- Lead Sponsor
- Yale University
- Target Recruit Count
- 11
- Registration Number
- NCT00411788
- Locations
- 🇺🇸
Yale Comprehensive Cancer Center at Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸Bridgeport Hospital, Bridgeport, Connecticut, United States
Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer
- First Posted Date
- 2006-11-27
- Last Posted Date
- 2017-12-22
- Lead Sponsor
- George Albert Fisher
- Target Recruit Count
- 21
- Registration Number
- NCT00404066
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
🇺🇸Santa Clara Valley Medical Center, San Jose, California, United States
HERVIN: Trastuzumab and Vinorelbine in Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2006-11-20
- Last Posted Date
- 2012-07-13
- Lead Sponsor
- National Cancer Institute, Naples
- Target Recruit Count
- 50
- Registration Number
- NCT00401427
Trastuzumab, Cyclophosphamide, and an Allogeneic GM-CSF-secreting Breast Tumor Vaccine for the Treatment of HER-2/Neu-Overexpressing Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-11-15
- Last Posted Date
- 2020-04-22
- Target Recruit Count
- 22
- Registration Number
- NCT00399529
- Locations
- 🇺🇸
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer
- First Posted Date
- 2006-11-10
- Last Posted Date
- 2018-07-24
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT00398567
- Locations
- 🇺🇸
Duke University, Duke University Medical Center, Durham, North Carolina, United States
🇺🇸LAC/USC Medical Center, USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of Maryland, University of Maryland Medical Center, Baltimore, Maryland, United States
Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+ Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-10-26
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 29
- Registration Number
- NCT00392392
- Locations
- 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸Florida Hospital Cancer Institute, Orlando, Florida, United States
Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-10-13
- Last Posted Date
- 2016-05-05
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 6
- Registration Number
- NCT00387907
- Locations
- 🇺🇸
Sanofi-Aventis Administrative Office, Malvern, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.